作者
Ashraf Fawzy, Nirupama Putcha, Carrie P Aaron, Russell P Bowler, Alejandro P Comellas, Christopher B Cooper, Mark T Dransfield, MeiLan K Han, Eric A Hoffman, Richard E Kanner, Jerry A Krishnan, Wassim W Labaki, Robert Paine III, Laura M Paulin, Stephen P Peters, Robert Wise, R Graham Barr, Nadia N Hansel, Neil E Alexis, Wayne H Anderson, Igor Barjaktarevic, Eugene R Bleecker, Richard C Boucher, Elizabeth E Carretta, Stephanie A Christenson, David J Couper, Gerard J Criner, Ronald G Crystal, Jeffrey L Curtis, Claire M Doerschuk, Christine M Freeman, Annette T Hastie, Robert J Kaner, Eric C Kleerup, Lisa M LaVange, Stephen C Lazarus, Fernando J Martinez, Deborah A Meyers, Wendy C Moore, John D Newell Jr, Laura Paulin, Stephen Peters, Cheryl Pirozzi, Elizabeth C Oelsner, Wanda K O’Neal, Victor E Ortega, Sanjeev Raman, Stephen I Rennard, Donald P Tashkin, J Michael Wells, Robert A Wise, Prescott G Woodruff
发表日期
2019/3/1
期刊
Chest
卷号
155
期号
3
页码范围
519-527
出版商
Elsevier
简介
Background
Aspirin use in COPD has been associated with reduced all-cause mortality in meta-regression analysis with few equivocal studies. However, the effect of aspirin on COPD morbidity is unknown.
Methods
Self-reported daily aspirin use was obtained at baseline from SPIROMICS participants with COPD (FEV1/FVC < 70%). Acute exacerbations of COPD (AECOPD) were prospectively ascertained through quarterly structured telephone questionnaires up to 3 years and categorized as moderate (symptoms treated with antibiotics or oral corticosteroids) or severe (requiring ED visit or hospitalization). Aspirin users were matched one-to-one with nonusers, based on propensity score. The association of aspirin use with total, moderate, and severe AECOPD was investigated using zero-inflated negative binomial models. Linear or logistic regression was used to investigate the association with baseline respiratory …
引用总数
201920202021202220232024363975